A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

Exclusion Criteria

• •The patient may not enter the study if ANY of the following apply:
• •Taking any concomitant medications or drugs which could interact with the study medications or have antiviral activity
• •Presence of any chronic illness/condition requiring long term treatment or other significant comorbidity
• •BMI ≥35 Kg/m2
• •Clinically relevant laboratory abnormalities discovered at screening
• •* Haemoglobin \<10g/dL
• •* Platelet count \<100,000/uL
• •* ALT \> 2x ULN
• •* Total bilirubin \>1.5 x ULN
• •* eGFR \<70mls/min/1.73m2
• •For females: pregnancy, actively trying to become pregnant or lactation (healthy women on OCP are eligible to join)
• •Contraindication to taking, or known hypersensitivity reaction to any of the proposed therapeutics
• •Currently participating in another interventional influenza or COVID-19 therapeutic trial
• •Clinical evidence of pneumonia- e.g. shortness of breath, hypoxaemia, crepitations (imaging not required)
• •Known to be currently co-infected with SARS-CoV-2 (i.e. confirmed with positive ATK or RT-PCR)
• •Received live attenuated influenza virus vaccine within 3 weeks prior to study entry